Stocks Sold by Mutual Funds in March 2025
Stocks Sold by Mutual Funds in March 2025

Stocks Sold by Mutual Funds in March 2025

As markets rallied, mutual funds booked profits and pared down holdings across large-cap, mid-cap, and small-cap stocks — here’s a look at where the selling happened.

DSIJ Intelligence Article rating: 5.0

As markets rallied, mutual funds booked profits and pared down holdings across large-cap, mid-cap, and small-cap stocks — here’s a look at where the selling happened.

Mutual Funds Pick Their Bets: Stocks Bought in March 2025
Mutual Funds Pick Their Bets: Stocks Bought in March 2025

Mutual Funds Pick Their Bets: Stocks Bought in March 2025

Despite a choppy market and declining inflows, mutual funds continued to bet on select large-cap, mid-cap, and small-cap stocks — here’s a look at what they bought.

DSIJ Intelligence Article rating: 5.0

Despite a choppy market and declining inflows, mutual funds continued to bet on select large-cap, mid-cap, and small-cap stocks — here’s a look at what they bought.

In conversation with Kailash Kulkarni, Chief Executive Officer, HSBC Mutual Fund
In conversation with Kailash Kulkarni, Chief Executive Officer, HSBC Mutual Fund

In conversation with Kailash Kulkarni, Chief Executive Officer, HSBC Mutual Fund

“While various scenarios are being built on the possible impact of tariff policies, they are unlikely to change the long-term India growth story”, affirms Kailash Kulkarni, Chief Executive Officer, HSBC Mutual Fund

DSIJ Intelligence Article rating: 4.5

“While various scenarios are being built on the possible impact of tariff policies, they are unlikely to change the long-term India growth story”, affirms Kailash Kulkarni, Chief Executive Officer, HSBC Mutual Fund

Top Performing Pharma and Healthcare Mutual Funds in Last 3 Years
Top Performing Pharma and Healthcare Mutual Funds in Last 3 Years

Top Performing Pharma and Healthcare Mutual Funds in Last 3 Years

Indian pharmaceutical stocks surged 5 per cent on Thursday, defying a broader market decline, following the U.S. administration's decision to exempt pharmaceutical products from new reciprocal tariffs.

DSIJ Intelligence-2 Article rating: 5.0

Indian pharmaceutical stocks surged 5 per cent on Thursday, defying a broader market decline, following the U.S. administration's decision to exempt pharmaceutical products from new reciprocal tariffs.

Equity Mutual Fund Inflows Drop 26 per cent to Rs 29,303 Crore in February as AUM Falls 4.04 per cent Amid Market Correction; Rs 6,525 Crore Outflow in Debt Schemes
Equity Mutual Fund Inflows Drop 26 per cent to Rs 29,303 Crore in February  as AUM Falls 4.04 per cent Amid Market Correction; Rs 6,525 Crore Outflow in Debt Schemes

Equity Mutual Fund Inflows Drop 26 per cent to Rs 29,303 Crore in February as AUM Falls 4.04 per cent Amid Market Correction; Rs 6,525 Crore Outflow in Debt Schemes

The total inflows standing at Rs 40,063 crore in February compared to Rs 1,87,550 crore in January, according to data from the Association of Mutual Funds of India (AMFI) released on March 12.

DSIJ Intelligence-2 Article rating: 5.0
IndusInd Bank Shares Crash 26 Per cent Due to Rs 1,580 Crore Forex Derivative Loss; Here are Top 5 Mutual Funds Holding the Stock
IndusInd Bank Shares Crash 26 Per cent Due to Rs 1,580 Crore Forex Derivative Loss; Here are Top 5 Mutual Funds Holding the Stock

IndusInd Bank Shares Crash 26 Per cent Due to Rs 1,580 Crore Forex Derivative Loss; Here are Top 5 Mutual Funds Holding the Stock

IndusInd Bank shares fell 26 per cent due to forex derivative misaccounting, resulting in a Rs 1,580 crore loss. Analysts downgraded the stock, citing governance concerns and earnings pressure.

DSIJ Intelligence-2 Article rating: 3.6

DSIJ MINDSHARE

Mkt Commentary22-Apr, 2025

Mindshare22-Apr, 2025

Penny Stocks22-Apr, 2025

Mindshare22-Apr, 2025

Multibaggers22-Apr, 2025

Knowledge

MF22-Apr, 2025

MF17-Apr, 2025

General22-Mar, 2025

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR